FDA Peptide Compounding Policy 2026: BPC-157, Expected Timeline, and What Pharmacies Need to Know
FDA's proposed BPC-157 and peptide compounding policy is under OIRA review, with a new October 21 stakeholder meeting. What 503A/503B pharmacies and telehealth companies should do now.


